Ricardo Cuadra, MD
Internal Medicine · Houston, TXNPI 1144251372
Payments from drug & device makers
Across 368 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amarin Pharma, Inc.$787
- AbbVie$765
- Boehringer Ingelheim$534
- AstraZeneca$517
- Johnson & Johnson$271
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,37198%
- Education$1322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $1,129 |
| Amarin Pharma, Inc. | 48 | $787 |
| AbbVie(2 entities) | 58 | $765 |
| Boehringer Ingelheim | 24 | $534 |
| AstraZeneca | 31 | $517 |
| Johnson & Johnson | 16 | $271 |
| Otsuka America Pharmaceutical, Inc. | 10 | $231 |
| Pfizer | 8 | $212 |
| Amgen | 11 | $196 |
| Lilly USA, LLC | 9 | $174 |
| Astellas Pharma US Inc | 5 | $168 |
| Sanofi-aventis U.S. LLC | 9 | $164 |
| Bayer | 9 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $160 |
| GSK | 7 | $121 |
| Sunovion Pharmaceuticals Inc. | 8 | $115 |
| Perspectum Diagnostics Ltd | 2 | $98 |
| Abbott | 5 | $93 |
| Dexcom, Inc. | 2 | $79 |
| Novartis | 4 | $72 |
| Althera Pharmaceuticals LLC | 3 | $68 |
| Ironwood Pharmaceuticals, Inc | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Lundbeck LLC | 2 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $31 |
| Insulet Corporation | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Boston Scientific | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Merck | 1 | $11 |
How this compares
$6,503 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 139 | $143,738 |
| JardianceEmpagliflozin | 147 | $140,425 |
| OzempicSemaglutide | 91 | $124,823 |
| EliquisApixaban | 143 | $98,702 |
| TrulicityDulaglutide | 27 | $56,597 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $43,519 |
| LinzessLinaclotide | 46 | $40,651 |
| XareltoRivaroxaban | 25 | $40,151 |
| JanuviaSitagliptin Phosphate | 54 | $34,885 |
| MyrbetriqMirabegron | 27 | $34,791 |
| GemtesaVibegron | 22 | $31,359 |
| EntrestoSacubitril/Valsartan | 22 | $30,142 |
| TradjentaLinagliptin | 54 | $29,315 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $20,467 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $10,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $534 | $180,682213 claims |
| AstraZenecaFarxiga, Brilinta | $517 | $149,832162 claims |
| Novo NordiskOzempic | $1,129 | $124,82391 claims |
| PfizerEliquis | $212 | $98,702143 claims |
| Lilly USA, LLCTrulicity | $174 | $56,59727 claims |
| AbbVieLinzess, Creon | $765 | $46,34858 claims |
| Johnson & JohnsonXarelto | $271 | $40,15125 claims |
| MerckJanuvia | $11 | $34,88554 claims |
| Astellas Pharma US IncMyrbetriq | $168 | $34,79127 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $31,35922 claims |
| NovartisEntresto | $72 | $30,14222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.